147 related articles for article (PubMed ID: 37104249)
21. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
Wang HJ; Pochampalli M; Wang LY; Zou JX; Li PS; Hsu SC; Wang BJ; Huang SH; Yang P; Yang JC; Chu CY; Hsieh CL; Sung SY; Li CF; Tepper CG; Ann DK; Gao AC; Evans CP; Izumiya Y; Chuu CP; Wang WC; Chen HW; Kung HJ
Oncogene; 2019 Jan; 38(1):17-32. PubMed ID: 30072740
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.
Zhang Z; Wang X; Kim M; He D; Wang C; Fong KW; Liu X
Prostate; 2023 Nov; 83(15):1458-1469. PubMed ID: 37475584
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
24. Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
Chang T; Lian Z; Ma S; Liang Z; Ma X; Wen X; Wang Y; Liu R
Prostate; 2023 Apr; 83(5):470-486. PubMed ID: 36576015
[TBL] [Abstract][Full Text] [Related]
25. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
26. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
27. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
[TBL] [Abstract][Full Text] [Related]
28. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
29. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
30. Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression.
Xu H; Xu K; He HH; Zang C; Chen CH; Chen Y; Qin Q; Wang S; Wang C; Hu S; Li F; Long H; Brown M; Liu XS
Mol Cancer Res; 2016 Feb; 14(2):163-172. PubMed ID: 26659825
[TBL] [Abstract][Full Text] [Related]
31. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
Deb G; Shankar E; Thakur VS; Ponsky LE; Bodner DR; Fu P; Gupta S
Mol Carcinog; 2019 Jul; 58(7):1194-1207. PubMed ID: 30854739
[TBL] [Abstract][Full Text] [Related]
32. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
[TBL] [Abstract][Full Text] [Related]
33. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Zhang A; Lau NA; Wong A; Brown LG; Coleman IM; De Sarkar N; Li D; DeLucia DC; Labrecque MP; Nguyen HM; Conner JL; Dumpit RF; True LD; Lin DW; Corey E; Alumkal JJ; Nelson PS; Morrissey C; Lee JK
Cancer Res Commun; 2023 Nov; 3(11):2358-2374. PubMed ID: 37823778
[TBL] [Abstract][Full Text] [Related]
34. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway.
Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
[TBL] [Abstract][Full Text] [Related]
35. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.
Eigl BJ; North S; Winquist E; Finch D; Wood L; Sridhar SS; Powers J; Good J; Sharma M; Squire JA; Bazov J; Jamaspishvili T; Cox ME; Bradbury PA; Eisenhauer EA; Chi KN
Invest New Drugs; 2015 Aug; 33(4):969-76. PubMed ID: 25983041
[TBL] [Abstract][Full Text] [Related]
37. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
[TBL] [Abstract][Full Text] [Related]
38. HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo.
Xiang S; Zou P; Tang Q; Zheng F; Wu J; Chen Z; Hann SS
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):589-599. PubMed ID: 29221985
[TBL] [Abstract][Full Text] [Related]
39. Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists.
McCann C; Crawford N; Majkut J; Holohan C; Armstrong CWD; Maxwell PJ; Ong CW; LaBonte MJ; McDade SS; Waugh DJ; Longley DB
Cell Death Dis; 2018 Oct; 9(11):1081. PubMed ID: 30349042
[TBL] [Abstract][Full Text] [Related]
40. SETting Up for Epigenetic Regulation of Advanced Prostate Cancer.
Thienger P; Rubin MA
Cancer Cell; 2020 Sep; 38(3):309-311. PubMed ID: 32931739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
